SMC approval of Cosentyx as first-line

biologic for treatment of nr-axSpA

Thursday 25th March 2021, 19:00–20:30

Spot_Light_Background.png

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited.

UK | March 2021 | 108907

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.UK/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.